Page last updated: 2024-11-02

oxybutynin and Pain

oxybutynin has been researched along with Pain in 77 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"Our results indicated that incorporating a QR code within additional video education leads to proper use of a fentanyl transdermal patch and relieves pain and anxiety levels in patients with cancer."9.34Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020)
"Local injection of lidocaine provided clinically similar analgesia compared to the lidocaine/tetracaine patch during I&D of skin abscesses in the ED."9.19Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial. ( Bourne, CL; Brewer, KL; House, J, 2014)
"The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment, although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application."9.19A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. ( Bischoff, JM; Petersen, M; Ringsted, TK; Sommer, C; Uçeyler, N; Werner, MU, 2014)
"The primary efficacy endpoint, mean difference between the two treatment arms in an 11-point numerical pain rating scale from baseline to 2 weeks after patch applications, was significantly lower on the capsaicin 8% patch treatment arm [P=0."9.19Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. ( Anand, P; Gibbs, JS; Gin-Sing, W; Huson, L; Iddamalgoda, T; Khengar, RH; Libri, V; Pinato, DJ, 2014)
"Topical capsaicin 8% was developed for the treatment of peripheral neuropathic pain."9.17Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. ( Knolle, E; Kovacs, GG; Medwed, S; Scharbert, G; Schemper, M; Zadrazil, M, 2013)
"Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57."9.16[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. ( Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)
"To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain."9.15Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011)
"3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia."9.15Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011)
"This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia."9.15Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011)
"The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain."9.14Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010)
"Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)."8.90Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014)
"The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine."8.88Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012)
"This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug."8.87Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011)
"Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain."7.81The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015)
"It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)."7.80A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014)
"Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment."7.78Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012)
"Opioid introduction to opioid-naÏve outpatients with cancer pain using the low-dose fentanyl patch (2."7.77[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011)
" However, oral nonsteroidal anti-inflammatory drugs cause several adverse events, with topical formulations arising as an important alternative."6.90Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial. ( Daher, MT; Fujiki, EN; Kraychete, DC; Lopes, DG; Nakamoto, A; Netto, NA; Tardini, R, 2019)
" The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46."6.82The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016)
"Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)."6.76Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011)
"Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)."6.46Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010)
"Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population."5.91Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023)
"Fentanyl has a low molecular weight and is lipophilic making it suitable for transdermal administration."5.51Unusual case of transdermal fentanyl in cachexia. ( Harrison, S; Kay, S; Lam, D; Pickard, J, 2019)
"Lidocaine patches are a safe, effective adjunct for rib fracture pain."5.37Lidocaine patches reduce pain in trauma patients with rib fractures. ( Mayberry, JC; Peck, EG; Schreiber, MA; Zink, KA, 2011)
"Our results indicated that incorporating a QR code within additional video education leads to proper use of a fentanyl transdermal patch and relieves pain and anxiety levels in patients with cancer."5.34Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020)
" Patients received stepwise pain treatment in which those who did not use analgesics were randomized to receive either paracetamol (3 g/day) or placebo tablets; those who already used pain treatment were allocated to buprenorphine transdermal system (max."5.27Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial. ( Bjorvatn, B; Blytt, KM; Flo, E; Husebo, B, 2018)
"The primary efficacy endpoint, mean difference between the two treatment arms in an 11-point numerical pain rating scale from baseline to 2 weeks after patch applications, was significantly lower on the capsaicin 8% patch treatment arm [P=0."5.19Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. ( Anand, P; Gibbs, JS; Gin-Sing, W; Huson, L; Iddamalgoda, T; Khengar, RH; Libri, V; Pinato, DJ, 2014)
"The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment, although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application."5.19A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. ( Bischoff, JM; Petersen, M; Ringsted, TK; Sommer, C; Uçeyler, N; Werner, MU, 2014)
"Local injection of lidocaine provided clinically similar analgesia compared to the lidocaine/tetracaine patch during I&D of skin abscesses in the ED."5.19Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial. ( Bourne, CL; Brewer, KL; House, J, 2014)
" According to a predefined scheme for 8 weeks, all patients in the intervention group received individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline."5.19The response of agitated behavior to pain management in persons with dementia. ( Aarsland, D; Ballard, C; Cohen-Mansfield, J; Husebo, BS; Seifert, R, 2014)
"Pain medication significantly improved pain in the intervention group, with indications that acetaminophen also improved ADL function."5.19Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. ( Aarsland, D; Ballard, C; Corbett, A; Husebo, BS; Sandvik, RK; Seifert, R; Selbaek, G, 2014)
"Twenty-two healthy males were included in a randomized study to assess the changes in EPs after 110 sweeps of painful electrical stimulation to the median nerve following treatment with buprenorphine, fentanyl or placebo patches."5.17A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials. ( Andresen, T; Arendt-Nielsen, T; Drewes, AM; Gram, M; Graversen, C; Mørch, CD; Nielsen, AK, 2013)
"Topical capsaicin 8% was developed for the treatment of peripheral neuropathic pain."5.17Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. ( Knolle, E; Kovacs, GG; Medwed, S; Scharbert, G; Schemper, M; Zadrazil, M, 2013)
"Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57."5.16[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. ( Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012)
"Topical lidocaine (5%) leads to sufficient pain relief in only 29%-80% of treated patients, presumably by small-fiber block."5.16Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. ( Krumova, EK; Maier, C; Westermann, A; Zeller, M, 2012)
"VAS pain scores during arterial puncture were comparable in both groups and Rapydan was non-inferior to subcutaneous lidocaine."5.16Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. ( Dunkler, D; Golescu, A; Grubhofer, G; Hoeferl, M; Hutschala, D; Jaeger, W; Mayer, L; Ruetzler, K; Sessler, DI; Sima, B; You, J, 2012)
"3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia."5.15Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011)
"This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia."5.15Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011)
"To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain."5.15Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011)
" Of the volunteers who received the nicotine patch, four became anorexic and nauseated and two required anti-emetics."5.15A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment. ( Fukada, T; Iwakiri, H; Ozaki, M, 2011)
"The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain."5.14Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010)
"Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)."4.90Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014)
"The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine."4.88Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012)
"This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug."4.87Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011)
" Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief."4.31Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating. ( Ishii, H; Kanai, A; Kokubun, H; Tabata, KI, 2023)
"Preclinical Research The aim of this study was to evaluate the efficacy of multiple applications of S(+)-flurbiprofen plaster (SFPP), a novel Nonsteroidal anti-inflammatory drug (NSAID) patch, for the alleviation of inflammatory pain and edema in rat adjuvant-induced arthritis (AIA) model as compared to other NSAID patches."3.83Topical Anti-Inflammatory and Analgesic Effects of Multiple Applications of S(+)-Flurbiprofen Plaster (SFPP) in a Rat Adjuvant-Induced Arthritis Model. ( Hori, M; Ichihara, T; Kaku, S; Matsumoto, H; Mitani, A; Otsuka, N; Sekine, S; Sugimoto, M; Toda, Y, 2016)
"This study was designed to formulate a drug in adhesive transdermal patch with codeine (CDB) and acetaminophen (APAP) that may potentially treat moderate pain in children."3.83Formulation optimization of a drug in adhesive transdermal analgesic patch. ( Abla, MJ; Banga, AK; Herwadkar, AK; Little, J; Ravula, R, 2016)
"Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain."3.81The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015)
"This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl."3.80Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ( Bandak, B; Barratt, DT; Christrup, LL; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA; Tuke, J, 2014)
"It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)."3.80A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014)
"Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment."3.78Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012)
"Opioid introduction to opioid-naÏve outpatients with cancer pain using the low-dose fentanyl patch (2."3.77[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011)
" We analyzed data from 5 open-label clinical trials of lidocaine patch 5% in osteoarthritis knee pain and chronic low back pain that were 2 to 12 weeks in duration."3.77Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. ( Dworkin, RH; Galer, BS; Gammaitoni, AR; Gould, E; Jensen, MP; Jones, BA; Xiang, Q, 2011)
" However, oral nonsteroidal anti-inflammatory drugs cause several adverse events, with topical formulations arising as an important alternative."2.90Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial. ( Daher, MT; Fujiki, EN; Kraychete, DC; Lopes, DG; Nakamoto, A; Netto, NA; Tardini, R, 2019)
"Warts are a common skin disease caused by infection of the human papilloma virus."2.87Efficacy of a bleomycin microneedle patch for the treatment of warts. ( Baek, JO; Jeong, HR; Kim, HJ; Kim, JS; Lee, SK; Park, JH; Roh, JY; Ryu, HR; Seon-Woo, HS, 2018)
" The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46."2.82The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016)
"nausea, constipation, dizziness and headache) were recorded after 6 and 12 days of treatment."2.78Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail. ( Bu, J; Du, Y; Fu, T; Huang, X; Lin, J; Tan, W; Wang, C; Wei, G, 2013)
" The most common adverse events were treatment site related (n=16, 7."2.76Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury. ( Carr, W; Kuehl, K; Magelli, M; Rovati, S; Yanchick, J, 2011)
"Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)."2.76Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011)
" The primary outcome measure was reduction in ureteral stent symptoms, and the secondary outcome measure was the safety of intravesical instillation of each agent through assessment of drug-related adverse events."2.71Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. ( Beiko, DT; Brock, GB; Denstedt, JD; Knudsen, BE; Nott, L; Pautler, SE; Razvi, H; Watterson, JD, 2004)
"Topical NSAIDs were effective and safe for OA."2.58Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. ( Doherty, M; Lei, G; Li, J; Li, X; Long, H; Persson, MSM; Sarmanova, A; Wang, Y; Wei, J; Xie, D; Zeng, C; Zhang, W, 2018)
"Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)."2.46Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010)
"Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population."1.91Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023)
"Its goal was to see how a transdermal fentanyl patch combined with accelerated recovery after surgery (ERAS) affected the treatment efficacy and analgesic effect of liver cancer, as well as to help patients with liver cancer choose the right analgesic treatment and nursing mode."1.72Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer. ( Fang, S; Lu, G; Xiao, H; Zhu, H, 2022)
"Elderly with dementia are prescribed opioids more frequent than elderly without."1.56The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia? ( Christensen, AN; Gasse, C; Jensen-Dahm, C; Waldemar, G, 2020)
" We assessed the proportion of users with prior tolerance stratified by dosage strength of FTS using four definitions of opioid tolerance: ≥30-mg oxycodone equivalents/day in each of 7 consecutive days immediately prior to index; ≥30-mg oxycodone equivalents/day for any 7 days in the 30 days prior to index (secondary); any dose in each of 7 days in the 7 consecutive days immediately prior to index (tertiary); and any dose for any 7 days in the 30 days prior to index (quaternary)."1.51Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA's Sentinel System. ( Cocoros, NM; Ju, J; Kornegay, C; Larochelle, MR; Petrone, AB; Popovic, J; Racoosin, JA, 2019)
"Fentanyl has a low molecular weight and is lipophilic making it suitable for transdermal administration."1.51Unusual case of transdermal fentanyl in cachexia. ( Harrison, S; Kay, S; Lam, D; Pickard, J, 2019)
"Fentanyl is an opioid analgesic that is available as injection and transdermal patch products for the management of acute and chronic pain."1.51Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity. ( Ajjarapu, SS; Bae, J; Dhawan, T; Maurya, A; Murthy, SN; Rangappa, S, 2019)
"The prevention of venipuncture-induced cancer pain requires a structured training program, which should reflect the views of nurses in clinical practice."1.46Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study. ( Chabloz, C; Chirac, A; Collin, C; Filbet, M; Larkin, P; Monsarrat, L; Rhondali, W; Ruer, M, 2017)
" Meanwhile, the ISO-C10 contained patches increased the drug disposition in synovial fluid and enhanced the pharmacodynamic efficacy of the formulation."1.42Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ( Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015)
" The potential efficacy of these MN for paediatric dosing was investigated via in vitro and in vivo studies."1.42Potential of hydrogel-forming and dissolving microneedles for use in paediatric populations. ( Caffarel-Salvador, E; Donnelly, RF; McCarthy, HO; McElnay, JC; Mooney, K; Tuan-Mahmood, TM; Woolfson, AD, 2015)
"Pain was the most common adverse reaction reported."1.40Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. ( Hägg, S; Holmlund, M; Lövborg, H, 2014)
"Lidocaine patches are a safe, effective adjunct for rib fracture pain."1.37Lidocaine patches reduce pain in trauma patients with rib fractures. ( Mayberry, JC; Peck, EG; Schreiber, MA; Zink, KA, 2011)

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (1.30)29.6817
2010's67 (87.01)24.3611
2020's9 (11.69)2.80

Authors

AuthorsStudies
Raisin, G1
Dothan, D1
Perez, D1
Ala-Adin, N1
Kafka, I1
Shenfeld, O1
Hatumi, S1
Malchi, N1
Gordon, A2
Touitou, D1
Moldwin, R1
Nassar, T1
Chertin, B1
Beiko, DT1
Watterson, JD1
Knudsen, BE1
Nott, L1
Pautler, SE1
Brock, GB1
Razvi, H1
Denstedt, JD1
Castilla-Casadiego, DA1
Miranda-Muñoz, KA1
Roberts, JL1
Crowell, AD1
Gonzalez-Nino, D1
Choudhury, D1
Aparicio-Solis, FO1
Servoss, SL1
Rosales, AM1
Prinz, G1
Zou, M1
Zhang, Y2
Coetzee, JF1
Greenlee, LF1
Powell, J1
Almodovar, J1
Zhu, H1
Xiao, H1
Lu, G1
Fang, S1
Nihadha, PM1
Chugh, A1
Kaur, A1
Kumar, S1
Naveen, KH1
Bhatia, PK1
Kumar, P1
Chaudhry, K1
Dietrich, CG1
Kottmann, T1
Voß, HW1
Lorenz, R1
Ishii, H3
Kokubun, H4
Tabata, KI3
Kanai, A3
Jensen-Dahm, C1
Christensen, AN1
Gasse, C1
Waldemar, G1
Ye, Z1
Chen, J1
Hu, X1
Xuan, Z1
Yang, S1
Mao, X1
Rao, Y1
Light, A1
Heininger, A1
Wessman, K1
Frutiger, K1
White, RJ1
Ryu, HR1
Jeong, HR1
Seon-Woo, HS1
Kim, JS1
Lee, SK1
Kim, HJ1
Baek, JO1
Park, JH1
Roh, JY1
Blytt, KM1
Bjorvatn, B1
Husebo, B1
Flo, E1
Zeng, C1
Wei, J1
Persson, MSM1
Sarmanova, A1
Doherty, M1
Xie, D1
Wang, Y1
Li, X1
Li, J1
Long, H1
Lei, G1
Zhang, W1
Cocoros, NM1
Larochelle, MR1
Popovic, J1
Petrone, AB1
Kornegay, C1
Ju, J1
Racoosin, JA1
Gisev, N1
Pearson, SA2
Larance, B1
Larney, S1
Blanch, B1
Degenhardt, L1
Feragalli, B1
Dugall, M1
Luzzi, R1
Ledda, A1
Hosoi, M1
Belcaro, G1
Cesarone, MR1
Lam, D1
Kay, S1
Pickard, J1
Harrison, S1
Ban, T1
Hirose, H1
Teraura, H1
Kotani, K1
Gotoh, T1
Zheng, D1
Narayan, SW1
Zoega, H1
Litchfield, M1
Buckley, NA1
Schaffer, AL1
Fujiki, EN1
Netto, NA1
Kraychete, DC1
Daher, MT1
Tardini, R1
Nakamoto, A1
Lopes, DG1
Yu, T1
Zhang, S1
Cao, X1
Liu, C1
Maurya, A1
Rangappa, S1
Bae, J1
Dhawan, T1
Ajjarapu, SS1
Murthy, SN1
Blanco-Antona, F1
González-Sarmiento, R1
García-Cenador, B1
Lozano, FS1
Lane, ME1
Bermejo, PE1
Zea, MA1
Alba-Alcántara, L1
Ruiz-Huete, C1
Gram, M1
Graversen, C1
Nielsen, AK1
Arendt-Nielsen, T1
Mørch, CD1
Andresen, T2
Drewes, AM2
Paparella, SF1
Husebo, BS2
Ballard, C2
Cohen-Mansfield, J1
Seifert, R2
Aarsland, D2
Mou, J1
Paillard, F1
Turnbull, B1
Trudeau, J1
Stoker, M1
Katz, NP1
Wang, C1
Tan, W1
Huang, X1
Fu, T1
Lin, J1
Bu, J1
Wei, G1
Du, Y1
Nalamachu, S1
Nalamasu, R1
Jenkins, J1
Marriott, T1
Knolle, E1
Zadrazil, M1
Kovacs, GG1
Medwed, S1
Scharbert, G1
Schemper, M1
Farr, BM1
Libri, V1
Gibbs, JS1
Pinato, DJ1
Iddamalgoda, T1
Khengar, RH1
Gin-Sing, W1
Huson, L1
Anand, P1
Therkleson, T1
Barratt, DT1
Bandak, B1
Klepstad, P1
Dale, O1
Kaasa, S1
Christrup, LL2
Tuke, J1
Somogyi, AA1
Ryazhenov, VV1
Abuzarova, GR1
Gorokhova, SG1
Emchenko, IV1
Matveev, NV1
Takahashi, H1
Chiba, T1
Tairabune, T1
Kimura, Y1
Wakabayashi, G1
Takahashi, K1
Kudo, K1
Sandvik, RK1
Selbaek, G1
Corbett, A1
Bourne, CL1
Brewer, KL1
House, J1
Lövborg, H1
Holmlund, M1
Hägg, S1
Bischoff, JM1
Ringsted, TK1
Petersen, M1
Sommer, C1
Uçeyler, N1
Werner, MU1
Kang, JH1
Oh, SY1
Song, SY1
Lee, HY1
Kim, JH1
Lee, KE1
Lee, HR1
Hwang, IG1
Park, SH1
Kim, WS1
Park, YS1
Park, K1
Caffarel-Salvador, E1
Tuan-Mahmood, TM1
McElnay, JC1
McCarthy, HO1
Mooney, K1
Woolfson, AD1
Donnelly, RF1
Chen, Y1
Quan, P1
Liu, X1
Guo, W1
Song, W1
Cun, D1
Wang, Z1
Fang, L1
Ravula, R1
Herwadkar, AK1
Abla, MJ1
Little, J1
Banga, AK1
Cheng, YJ1
Yataba, I1
Otsuka, N2
Matsushita, I1
Matsumoto, H2
Hoshino, Y1
Sugimoto, M1
Toda, Y1
Hori, M1
Mitani, A1
Ichihara, T1
Sekine, S1
Kaku, S1
Kaur, H1
Hwang, JC1
Ho, LY1
Zhang, X1
Ng, HJ1
Filbet, M1
Larkin, P1
Chabloz, C1
Chirac, A1
Monsarrat, L1
Ruer, M1
Rhondali, W1
Collin, C1
Nomura, M1
Kamata, M1
Kojima, H1
Hayashi, K1
Kozai, M1
Sawada, S1
McCarberg, BH1
Argoff, CE1
LoVecchio, F1
Ramos, L1
Dworkin, RH1
Jensen, MP1
Gould, E1
Jones, BA1
Xiang, Q1
Galer, BS1
Gammaitoni, AR1
Lam, VY1
Wallace, M1
Schulteis, G1
Botterman, J1
Criel, N1
Mercadante, S1
Porzio, G1
Ferrera, P1
Aielli, F1
Adile, C1
Ficorella, C1
Upton, RN1
Foster, DJ1
Arendt-Nielsen, L1
Hata, A1
Katakami, N1
Masuda, Y1
Nanjo, S1
Otsuka, K1
Kaji, R1
Fujita, S1
Iwamori, S1
Mifune, Y1
Orita, H1
Fukae, M1
Yamatani, T1
Kuehl, K1
Carr, W1
Yanchick, J1
Magelli, M2
Rovati, S2
Webster, LR1
Peppin, JF1
Murphy, FT1
Lu, B1
Tobias, JK1
Vanhove, GF1
Zink, KA1
Mayberry, JC1
Peck, EG1
Schreiber, MA1
Brewer, AR1
Pierchala, LA1
Yanchick, JK1
Fukada, T1
Iwakiri, H1
Ozaki, M1
Garbe, E1
Jobski, K1
Schmid, U1
Maathuis, MH1
Dijkstra, DD1
Barkin, RL1
Barkin, SJ1
Irving, GA1
Krumova, EK1
Zeller, M1
Westermann, A1
Maier, C1
Przeklasa-Muszyńska, A1
Dobrogowski, J1
Plosker, GL1
Wolff, RF1
Aune, D1
Truyers, C1
Hernandez, AV1
Misso, K1
Riemsma, R1
Kleijnen, J1
Harrison, AP1
Hansen, SH1
Bartels, EM1
Ikeda, M1
Sonoo, H1
Kurebayashi, J1
Oota, Y1
Fujii, S1
Shimo, T1
Mizutou, A1
Seki, M1
Saitou, W1
Yamashita, T1
Koike, Y1
Yamamoto, Y1
Shiiki, S1
Nakashima, K1
Tanaka, K1
Nomura, T1
Kubo, S1
Ebinuma, K1
Matoba, M1
Takayanagi, R1
Yamada, Y1
Yago, K1
Ruetzler, K1
Sima, B1
Mayer, L1
Golescu, A1
Dunkler, D1
Jaeger, W1
Hoeferl, M1
You, J1
Sessler, DI1
Grubhofer, G1
Hutschala, D1
Takakuwa, O1
Oguri, T1
Maeno, K1
Yokoyama, M1
Hijikata, H1
Uemura, T1
Ozasa, H1
Ohkubo, H1
Miyazaki, M1
Niimi, A1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized, Pilot Study of Preoperative Anti-Inflammatory Therapy for Ureteral Stent Symptoms[NCT03638999]Early Phase 136 participants (Anticipated)Interventional2018-07-31Recruiting
The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial[NCT01021696]Phase 2/Phase 3352 participants (Actual)Interventional2009-11-30Completed
A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Reduction of Site Pain Caused by Continuous Subcutaneous Infusion of Remodulin®, in Pulmonary Arterial Hypertension Patients[NCT01393795]Phase 211 participants (Actual)Interventional2011-08-31Completed
A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700]Phase 349 participants (Actual)Interventional2019-08-01Completed
[NCT01699854]Phase 350 participants (Anticipated)Interventional2012-08-31Terminated (stopped due to Expiration of the placebo patch)
Transdermal Microneedle Patch To Enhance Topical Anaesthesia Before Intravenous Line Insertion for Blood Transfusion In Paediatric Thalassemia Patients[NCT05078463]Phase 220 participants (Actual)Interventional2021-09-15Completed
Preventive Application Of Lidocaine Patch In Adjunction To Intravenous Morphine Analgesia For Management Of Post-Thoracotomy Pain: Results Of A Randomized, Double Blind, Placebo Controlled Study[NCT02751619]90 participants (Actual)Interventional2013-01-31Completed
A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain[NCT00082316]Phase 20 participants InterventionalCompleted
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297]301 participants (Anticipated)Interventional2022-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

NRS Pain Score After Blunt Dissection

Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl4.1
Placebo4.4

NRS Pain Score After Irrigation

Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl3.4
Placebo2.6

NRS Pain Score After Lidocaine Injection

Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl8.4
Placebo8.0

NRS Pain Score After Packing of Abscess

Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl4.5
Placebo3.9

NRS Pain Score Following Incision

Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl3.9
Placebo3.9

Numerical Rating Scale (NRS) Pain Score at Baseline

Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline

Interventionscore on a scale (Mean)
Intranasal Fentanyl8.3
Placebo8.1

Numerical Rating Scale (NRS) Pain Score for Overall Procedure

Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl6.2
Placebo7.0

Reviews

7 reviews available for oxybutynin and Pain

ArticleYear
Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
    British journal of sports medicine, 2018, Volume: 52, Issue:10

    Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Humans; Network M

2018
The transdermal delivery of fentanyl.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, Volume: 84, Issue:3

    Topics: Administration, Cutaneous; Analgesics; Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic;

2013
Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients.
    The Clinical journal of pain, 2014, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Capsaicin; Databases, Factual; Dose-Response Relationship, Drug; Dou

2014
Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.
    International journal of clinical practice, 2010, Volume: 64, Issue:11

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Contusions; Diclofenac; Humans; Pain; Soft Tiss

2010
Management of chronic noncancer pain in depressed patients.
    Postgraduate medicine, 2011, Volume: 123, Issue:5

    Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, N

2011
Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Drugs, 2011, Dec-24, Volume: 71, Issue:18

    Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Dose-Response Relationship, Drug; Humans; Pain;

2011
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
    Current medical research and opinion, 2012, Volume: 28, Issue:5

    Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human

2012

Trials

28 trials available for oxybutynin and Pain

ArticleYear
Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy.
    Journal of endourology, 2004, Volume: 18, Issue:8

    Topics: Administration, Intravesical; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Double-Bl

2004
Transdermal fentanyl patch versus standard analgesia in postoperative oral submucous fibrosis patients: a triple blinded, randomised control trial.
    The British journal of oral & maxillofacial surgery, 2022, Volume: 60, Issue:9

    Topics: Analgesia; Analgesics, Opioid; Fentanyl; Humans; Oral Submucous Fibrosis; Pain; Transdermal Patch

2022
Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Anxiety; Female; Fentanyl; Health Education; Humans; Male; Middle Ag

2020
Efficacy of a bleomycin microneedle patch for the treatment of warts.
    Drug delivery and translational research, 2018, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Bleomycin; Child; Child, Preschool; Cryotherapy; Female; Humans

2018
Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial.
    International journal of geriatric psychiatry, 2018, Volume: 33, Issue:4

    Topics: Acetaminophen; Adult; Aged; Analgesics; Buprenorphine; Dementia; Depressive Disorder; Double-Blind M

2018
Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial.
    Pain, 2019, Volume: 160, Issue:7

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brazil; Double-Blind Method; Extre

2019
Iontophoretic delivery of transdermal patches containi.
    Acta biochimica Polonica, 2019, Apr-15, Volume: 66, Issue:2

    Topics: Administration, Cutaneous; Anesthetics, Local; Animals; Child; Child, Preschool; Dialysis; Drug Comp

2019
A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials.
    British journal of clinical pharmacology, 2013, Volume: 76, Issue:6

    Topics: Adult; Analgesics, Opioid; Brain; Buprenorphine; Cross-Over Studies; Data Interpretation, Statistica

2013
The response of agitated behavior to pain management in persons with dementia.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2014, Volume: 22, Issue:7

    Topics: Acetaminophen; Aged, 80 and over; Analgesics; Buprenorphine; Delayed-Action Preparations; Dementia;

2014
Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2013, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Drugs, Chinese Herbal; Female; Humans; Male;

2013
Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study.
    Pain, 2013, Volume: 154, Issue:12

    Topics: Adult; Capsaicin; Cryotherapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Lidocaine; Li

2013
Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients.
    British journal of anaesthesia, 2014, Volume: 112, Issue:2

    Topics: Adult; Aged; Antihypertensive Agents; Capsaicin; Double-Blind Method; Epoprostenol; Female; Humans;

2014
Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.
    European journal of pain (London, England), 2014, Volume: 18, Issue:10

    Topics: Acetaminophen; Activities of Daily Living; Aged; Aged, 80 and over; Analgesics; Buprenorphine; Clini

2014
Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial.
    The Journal of emergency medicine, 2014, Volume: 47, Issue:3

    Topics: Abscess; Adolescent; Adult; Anesthesia, Local; Anesthetics, Local; Double-Blind Method; Female; Huma

2014
A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Adult; Aged; Capsaicin; Female; Hernia, Inguinal; Humans; Male; Middle Aged; Pain; Pain Management;

2014
Lidocaine Skin Patch (Lidopat® 5%) Is Effective in the Treatment of Traumatic Rib Fractures: A Prospective Double-Blinded and Vehicle-Controlled Study.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2016, Volume: 25, Issue:1

    Topics: Analgesics, Opioid; Anesthetics, Local; Double-Blind Method; Drug Utilization; Female; Humans; Lengt

2016
The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.
    Clinical drug investigation, 2016, Volume: 36, Issue:8

    Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Contact; Female;

2016
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:5

    Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F

2011
Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial.
    The journal of pain, 2011, Volume: 12, Issue:3

    Topics: Anesthetics, Local; Capsaicin; Double-Blind Method; Humans; Hyperalgesia; Injections, Intradermal; L

2011
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
    Current medical research and opinion, 2010, Volume: 26, Issue:12

    Topics: Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Mal

2010
Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:4

    Topics: Adult; Analgesics, Opioid; Buprenorphine; Capsaicin; Cold Temperature; Cross-Over Studies; Dose-Resp

2011
Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
    International journal of sports medicine, 2011, Volume: 32, Issue:8

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non

2011
Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
    Diabetes research and clinical practice, 2011, Volume: 93, Issue:2

    Topics: Aged; Anesthetics, Local; Capsaicin; Diabetic Neuropathies; Drug-Related Side Effects and Adverse Re

2011
A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment.
    European journal of anaesthesiology, 2011, Volume: 28, Issue:8

    Topics: Administration, Cutaneous; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Nau

2011
Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.
    Pain, 2012, Volume: 153, Issue:2

    Topics: Adult; Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Hyperalgesia; Lidocaine; Male;

2012
Transdermal buprenorphine in the treatment of cancer and non-cancer pain - the results of multicenter studies in Poland.
    Pharmacological reports : PR, 2011, Volume: 63, Issue:4

    Topics: Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Huma

2011
[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Therapy, Combin

2012
Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial.
    British journal of anaesthesia, 2012, Volume: 109, Issue:5

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Local; Anesthetic

2012

Other Studies

42 other studies available for oxybutynin and Pain

ArticleYear
Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St
    Urology, 2023, Volume: 178

    Topics: Administration, Intravesical; Cystitis, Interstitial; Delayed-Action Preparations; Humans; Lidocaine

2023
Biodegradable microneedle patch for delivery of meloxicam for managing pain in cattle.
    PloS one, 2022, Volume: 17, Issue:8

    Topics: Administration, Cutaneous; Animals; Cattle; Chitosan; Drug Delivery Systems; Meloxicam; Needles; Pai

2022
Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer.
    BioMed research international, 2022, Volume: 2022

    Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Enhanced Recovery After Surgery; Fentany

2022
Aloe Vera-Containing Matrix in Transdermal Fentanyl Therapy Improves Adhesion, Skin Tolerance and Quality of Life: Results of a German Multicenter Study with a New Fentanyl Patch.
    Drug research, 2023, Volume: 73, Issue:2

    Topics: Administration, Cutaneous; Aloe; Analgesics, Opioid; Fentanyl; Humans; Pain; Quality of Life; Transd

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms

2023
The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia?
    Journal of Alzheimer's disease : JAD, 2020, Volume: 73, Issue:1

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Behavioral Symptoms; Cross-Sectio

2020
8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain.
    Pain medicine (Malden, Mass.), 2017, 12-01, Volume: 18, Issue:12

    Topics: Aged; Antihypertensive Agents; Capsaicin; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Inf

2017
Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA's Sentinel System.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:1

    Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Child; Child, Preschool; Delayed-A

2019
A population-based study of transdermal fentanyl initiation in Australian clinical practice.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:3

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Australia

2019
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
    Minerva endocrinologica, 2019, Volume: 44, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Flavonoids; Humans; Inflammation; Knee; Male

2019
Unusual case of transdermal fentanyl in cachexia.
    BMJ supportive & palliative care, 2019, Volume: 9, Issue:4

    Topics: Analgesics, Opioid; Cachexia; Female; Fentanyl; Hospices; Humans; Middle Aged; Naloxone; Narcotic An

2019
Multiple physician visits after restricting the prescription of compresses/patches in a Japanese rural community: preliminary results.
    Rural and remote health, 2019, Volume: 19, Issue:1

    Topics: Administration, Topical; Aged; Aged, 80 and over; Female; Humans; Male; Office Visits; Osteoarthriti

2019
Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Australia; Buprenorphin

2019
Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity.
    International journal of pharmaceutics, 2019, Jun-10, Volume: 564

    Topics: Analgesics, Opioid; Animals; Drug Liberation; Fentanyl; Male; Microinjections; Needles; Pain; Rats,

2019
Transdermal Buprenorphine for Controlling Pain in Patients with Critical Lower-Limb Ischemia.
    Pain medicine (Malden, Mass.), 2020, 05-01, Volume: 21, Issue:5

    Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Humans; Ischemia; Pain; Pain Managemen

2020
[Local effects of transdermal treatment with rotigotine].
    Revista de neurologia, 2013, Apr-01, Volume: 56, Issue:7

    Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Evaluation; Drug Therapy, Combination; Equipment

2013
A serious threat to patient safety: the unintended misuse of FentaNYL patches.
    Journal of emergency nursing, 2013, Volume: 39, Issue:3

    Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Child, Preschool; Fatal Outcome; Female; Fentan

2013
An open-label pilot study evaluating the effectiveness of the heated lidocaine/tetracaine patch for the treatment of pain associated with carpal tunnel syndrome.
    Pain practice : the official journal of World Institute of Pain, 2014, Volume: 14, Issue:7

    Topics: Administration, Cutaneous; Adult; Carpal Tunnel Syndrome; Drug Combinations; Female; Hot Temperature

2014
Unclear study methods still confusing readers despite CONSORT guidelines (e.g., lidocaine patch does relieve pain of covered rib fractures).
    Journal of clinical epidemiology, 2014, Volume: 67, Issue:3

    Topics: Case-Control Studies; Guideline Adherence; Humans; Lidocaine; Pain; Pain Measurement; Periodicals as

2014
Topical Ginger Treatment With a Compress or Patch for Osteoarthritis Symptoms.
    Journal of holistic nursing : official journal of the American Holistic Nurses' Association, 2014, Volume: 32, Issue:3

    Topics: Administration, Topical; Aged; Female; Humans; Male; Middle Aged; New Zealand; Osteoarthritis; Pain;

2014
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily D, M

2014
[Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:2

    Topics: Ambulances; Analgesics, Opioid; Cost-Benefit Analysis; Economics, Pharmaceutical; Fentanyl; Health C

2014
A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neo

2014
Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.
    BMC pharmacology & toxicology, 2014, Jun-09, Volume: 15

    Topics: Adverse Drug Reaction Reporting Systems; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Medica

2014
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
    The Korean journal of internal medicine, 2015, Volume: 30, Issue:1

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum

2015
Potential of hydrogel-forming and dissolving microneedles for use in paediatric populations.
    International journal of pharmaceutics, 2015, Jul-15, Volume: 489, Issue:1-2

    Topics: Administration, Cutaneous; Adolescent; Analgesics; Animals; Caffeine; Child; Female; Humans; Hydroge

2015
Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:9

    Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutic

2015
Formulation optimization of a drug in adhesive transdermal analgesic patch.
    Drug development and industrial pharmacy, 2016, Volume: 42, Issue:6

    Topics: Acetaminophen; Adhesives; Administration, Cutaneous; Analgesics; Animals; Chemistry, Pharmaceutical;

2016
Topical Anti-Inflammatory and Analgesic Effects of Multiple Applications of S(+)-Flurbiprofen Plaster (SFPP) in a Rat Adjuvant-Induced Arthritis Model.
    Drug development research, 2016, Volume: 77, Issue:4

    Topics: Administration, Cutaneous; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis,

2016
Extensive subcutaneous haematoma associated with transdermal analgesic patch in a haemophilia A patient with inhibitor.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:4

    Topics: Adult; Analgesics, Opioid; Antibodies, Neutralizing; Factor VIIa; Hematoma; Hemoglobins; Hemophilia

2016
Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study.
    BMC palliative care, 2017, Jan-17, Volume: 16, Issue:1

    Topics: Adult; Analgesia; Attitude of Health Personnel; Clinical Competence; Clinical Protocols; Female; Hum

2017
Suicide by Duragesic transdermal fentanyl patch toxicity.
    The American journal of emergency medicine, 2011, Volume: 29, Issue:1

    Topics: Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Pain; Suicide; Transdermal Patch

2011
Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events.
    The journal of pain, 2011, Volume: 12, Issue:4

    Topics: Anesthetics, Local; Chronic Disease; Clinical Trials as Topic; Female; Humans; Lidocaine; Low Back P

2011
Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
    Palliative medicine, 2011, Volume: 25, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid;

2011
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi

2011
Lidocaine patches reduce pain in trauma patients with rib fractures.
    The American surgeon, 2011, Volume: 77, Issue:4

    Topics: Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Oregon; Pain; Retrospective Studie

2011
Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies.
    Postgraduate medicine, 2011, Volume: 123, Issue:4

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Gastrointesti

2011
Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:2

    Topics: Aged; Analgesics, Opioid; Databases, Factual; Dose-Response Relationship, Drug; Female; Fentanyl; Ge

2012
Disaster after the plaster. Fentanyl withdrawal symptoms in a curable hospice patient.
    The European journal of general practice, 2011, Volume: 17, Issue:4

    Topics: Aged, 80 and over; Analgesics, Opioid; Colonic Neoplasms; Drug Administration Schedule; Female; Fent

2011
Transdermal opioid patches for pain treatment in ancient Greece.
    Pain practice : the official journal of World Institute of Pain, 2012, Volume: 12, Issue:8

    Topics: Analgesics, Opioid; Animals; Greece, Ancient; History, Ancient; Humans; Male; Mice; Pain; Transderma

2012
Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
    Journal of pain & palliative care pharmacotherapy, 2012, Volume: 26, Issue:2

    Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Cytochrome P-450 CYP3A; Dose-Response Re

2012
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
    The American journal of hospice & palliative care, 2013, Volume: 30, Issue:7

    Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla

2013